INTRODUCTION
It is well known that deregulated expression of c-Myc is implicated in malignant transformation. In particular, c-Myc has a central role during malignant conversion in human hepatocarcinogenesis. 1 c-Myc is essential for biological events such as early embryogenesis, cell growth, differentiation and apoptosis. Myc has a C-terminal basic helix-loop-helix leucine zipper domain and two essential domains for interacting with a transcriptional coactivator within the N-terminal regulatory region (MbI and MbII; Kaposi-Noval et al. 2 and Amati et al. 3 ). The basic helix-loophelix leucine zipper domain is required for dimerizing with basic helix-loop-helix leucine zipper protein Max and binding to E-box DNA element. MbI and MbII are essential for interacting with TRRAP, which is a subunit of the histone acetyltransferase (HAT) complex. [4] [5] [6] HATs contribute to the regulation of chromatin structure and assembly of gene transcription. Several types of HAT have been identified, such as the SPT-ADA-GCN5-acetyltransferase (SAGA) complex, TATA-binding protein-free TAF-binding complex and SPT3-TAF9-GCN5-acetyltransferase (STAGA) complex. 7 Even if the substrate for several HATs overlaps, each HAT can perform its own specific task. Among these HAT subunits, TRRAP and GCN5, key subunits of these HATs, are essential for recruiting c-Myc to regulate transcription. 5 Sgf29 also has an important role in HATs. Recently, it has been reported that the SAGA complex binds to histone H3K4me2/3 marks through double Tudor domains in the C terminus of Sgf29. 8, 9 Sgf29 directly binds Ada3, a SAGA component and modulator of Gcn5 acetyltransferase activity, to induce the activation of c-Myc-targeted gene expression through acetylation of histone H3. 10 Downregulation of Sgf29 gives rise to inhibition of tumorigenicity and lung metastasis of aflatoxin B 1 -induced rat hepatocellular carcinoma (rHCC) K2 cells through suppression of genes involved in c-Myc-mediated malignant transformation. 10 Under these conditions, identification of an upstream regulator of Sgf29 would help to further elucidate c-Myc-mediated malignant transformation.
Sry (sex-determining region Y) contains a high-mobility group (HMG) domain, which is characteristic of Sox family members. 11 The HMG domain binds to a consensus DNA element (HMG-box; AACAAAG) in the minor groove and increases its binding affinity and specificity for the HMG-box by interacting with many types of transcription factors. 12 The Sry gene is under the control of an epigenetic mechanism mediated by DNA methylation in mouse gonadal development 13 and functions in testis development from bipotential gonads. Therefore, Sry is transiently expressed in sertoli cell precursors between embryonic day (E) 10.5 and E12.5.
14,15 Although Sry-targeted candidate genes are predicted, only Sox9 has been identified to date, in which Sry and SF-1 directly bind to TESCO (testis-specific enhancer of Sox9 core) and activate it synergistically. 16 It is well known that the structure of Sry is different among species, for example, SRY has a longer N-terminal region in Homo sapiens than that in Rattus norvegicus ortholog. However, these genes exhibit a common function as a master gene of sex determination in the embryonic stage. Nonetheless, whether Sry participates in c-Myc-mediated malignant transformation is still obscure.
In this study, using mainly male rHCC K2 and dRLa-74 cells, which overexpress c-Myc and Sgf29, 10, 17, 18 we focused on identification of the upstream regulator of the Sgf29 gene and found that Sry is a novel regulator of the Sgf29 gene. Downregulation of Sry suppressed tumorigenicity via inhibition of Sgf29 and c-Myc-targeted gene expressions, whereas ectopic expression of Sry conferred more malignant natures.
Thus, we first searched for possible upstream regulators of Sgf29 in silico. Ten candidate transcriptional factors including c-Myc, Sry, AML-1a and GATA-1 were found. Based on the existence of seven putative HMG-boxes in the promoter region ( À 1232 to À 53) of Sgf29 (Figure 2a ) and that its transcript is highly expressed in the testis, 10 we thought that Sry may be the most possible regulator of Sgf29 among the candidates. However, there is no report concerning the oncogenic function of Sry. Therefore, we analyzed the expression levels of Sry mRNA and protein in rHCC cells (aflatoxin B 1 -induced K2 cells, and 4-dimethylaminoazobenzene-induced AH66tc, AH70tc, dRLa-74 and dRLh-84 cells), rat glioblastoma C6, rat adrenal pheochromocytoma PC12 and non-tumor rat embryonic fibroblast REF52 cells by reverse transcription-polymerase chain reaction (RT-PCR) and western blotting (WB) with anti-Sry antibody, respectively. We have previously reported that in these rHCCs c-myc and 14-3-3b oncogenes were involved in the acquisition of malignant phenotypes, such as anchorageindependent growth, metastasis and tumorigenicity. 10, 17, 18 Unexpectedly, substantial expression of Sry mRNA and protein was observed in two male rHCCs tested, such as K2 and dRLa-74, as well as C6 and PC12 cells (Figures 1a-c) . On the other hand, expression levels of Sry mRNA and protein in female rHCC AH66tc and non-tumor REF52 cells were negligible relative to those in male rHCCs. Even though Sry mRNA expression levels in C6 cells were similar to those in dRLa-74 and PC12 cells, Sry protein expression level was extremely low (Figures 1b and c) . To test whether the ubiquitin/proteasome system is involved in the lowlevel Sry expression in C6 cells, 19 we investigated the effect of MG132, an inhibitor of proteasome, on the expression level of Sry. C6 cells were treated with various concentrations of MG132 for 24 h and analyzed by WB with anti-Sry antibody (Figures 1d and  e) . In the absence of MG132, Sry expression in C6 cells was a negligible level, whereas in the presence of MG132, its expression was dose-dependently upregulated and approximately 10-fold increment was observed at 5 mM. On the other hand, in K2 cells Sry expression was enhanced only 1.4-fold of the original level at 1 mM and decreased with X2 mM because of cell death, suggesting that the ubiquitin/proteasome system could be participated in posttranscriptional regulation of Sry in a cell type-dependent manner. Importantly, the expression level of Sgf29 is well correlated with Sry expression levels in these cell lines, except for C6 cells. These results imply that regulation of the stability of Sry mRNA and protein may be significantly different among these cells. In the following experiments, we used K2 cells because the functions of c-myc and Sgf29 genes in K2 cells have been analyzed in detail. 10, 17, 18, 20 To compare Sry expression levels among male HCC K2, female HCC AH66tc and normal male rat liver, RT-PCR analysis was performed using the rat testis as a positive control. Expression levels of Sry in K2 cells were equivalent to those in the testis, whereas its expression in the normal male rat liver and female HCC AH66tc cells was hardly detected (Figures 1f and g ). We then extracted genomic DNA from K2, AH66tc and REF52, whose DNA content is normally diploid (2n; Murray et al. 21 ), and analyzed the copy number of the Sry gene by genomic PCR. An approximately 2.4-fold amplification of the Sry gene was detected in K2 cells relative to that in REF52 cells (Figures 1h and i) . As expected, in AH66tc cells, Sox2, but not Sry, was detected and its copy number was equivalent to that of K2 and REF52 cells. Thus, high expression levels of Sry mRNA and protein in K2 cells may be partly caused by gene amplification, although we cannot rule out the possibility of DNA demethylation in the Sry promoter region. (Figure 2b ). The Sgf29 proximal promoter ( À 381 to À 53) regulating luciferase activity was dosedependently enhanced by Sry (Figure 2c ). To further analyze whether Sry directly binds to putative HMG-boxes in the Sgf29 proximal promoter, a chromatin immunoprecipitation (ChIP) assay with anti-Sry antibody was performed. The results showed that Sry could bind the putative HMG-boxes (Figures 2d and e). To further confirm the activation of the Sry promoter, ChIP analysis with antiacetylated histone H3 antibody was also carried out. As expected, antiacetylated histone H3 was detected in the putative region. Taken together, it seems that Sry could directly bind with the proximal HMG-boxes of Sgf29, at least in part, and activated gene expression via histone H3 acetylation. Downregulation of Sry inhibits the malignant properties of rHCC cells As described above, we showed that Sry could directly activate Sgf29 gene expression; therefore, we analyzed the oncogenic function of Sry using rHCC. To clarify the oncogenic function of Sry, we established the antisense Sry RNA expression vectorintroduced ASSry-1/2 K2 and dRLa-74 subcell lines (Figures 3a-d ). The difference in downregulation level of Sry among ASSry-1/2 K2 and dRLa-74 cells might be caused by the difference of integration sites in chromosomes and/or integrated copy number of antisense Sry expression vector. Sgf29 expression was dependent on Sry, and expression levels in these transfectants were significantly lower than those in vacant vector-introduced V1 cells. Moreover, as a result of Sgf29 downregulation, expression levels of typical c-Myc-targeted gene products such as lactate dehydrogenase A (LDHA) and metastasis-associated protein 1 (MTA1) were reduced. On the other hand, downregulation of Sry did not have a large effect on the expression of ornithine decarboxylase (ODC), one of the c-Myc downstream gene. When cultured in a monolayer in a medium containing 5% fetal bovine serum (FBS), there were no differences in growth rates among these cells (Figure 3e ). Nonetheless, in a medium containing 0.5% FBS, the growth rates of ASSry-1/2 K2 and dRLa-74 cells were robustly lower than those of V1 control cells (Figure 3f) , showing that downregulation of Sry induces dependence on serum for cell growth. The colonyforming ability of antisense Sry transfectants in the soft agar medium was also lower than those of V1 control cells (Figures 3g  and h ). In addition, invasive potencies of ASSry-1/2 K2 cells, assayed by a Matrigel-coated chamber, were lower than those of V1 control cells (Figures 3i and j To further confirm the oncogenic function of Sry, effects of ectopic expression of Sry on the malignant characteristics of dRLh-84 cells, whose expression levels of Sry mRNA and protein were lower than those of K2 and dRLa-74 cells, were investigated (Figures 1a-c) . Sense Sry expression vector-introduced dRLh-84 subcell lines Sry-1 and Sry-2 acquired elevated expression of Sgf29 and LDHA (Figures 5a and b) , reduced requirement of serum for growth (Figures 5c and d) and potent colony-forming ability in semisolid medium (Figures 5e and f) , as well as Sry-1/2 K2 and dRLa-74 transfectants. Thus, these results also imply that Sry possesses an oncogenic function and its deregulated expression is implicated in acquisition of malignant natures of rHCCs.
Involvement of Sgf29 in Sry-dependent acquisition of malignant natures To further elucidate that in the downstream of Sry signaling Sgf29 functions on the c-Myc target gene expressions as a member of STAGA coactivator complex, using Sgf29-downregulated K2 subcell line, SGAS1, whose expression levels c-Myc target genes and metastatic and tumorigenic potentials are extremely low compared with those in the parental K2 cells, 10 we analyzed the effect of transient expression of Sry on c-Myc target gene expressions. In SGAS1 cells, transient Sry expression did not cause any change in LDHA, ODC and MTA1 mRNA/protein expression levels (Figures 6a and b) . On the other hand, in K2 cells these gene expressions were induced by ectopic expression of Sry. These results showed that in the downstream of Sry signaling, Sgf29 had a critical role in c-Myc target gene expressions.
Taken together, these data firmly support the idea that Sry possesses an oncogenic function and its deregulated expression by gene amplification is implicated partly in male-specific acquisition of malignancy and hepatocarcinogenesis via activation of Sgf29/STAGA coactivator complex-dependent c-Myc function (Figure 6c ).
DISCUSSION
In this study, we showed that Sry activates Sgf29 gene expression via direct binding with HMG-boxes in the proximal promoter region of the Sgf29 gene, whose product is a component of the STAGA HAT complex. Gain and loss of functional analyses indicate that Sry is partly involved in c-Myc-mediated hepatocarcinogenesis. This is the first demonstration that deregulated expression of Sry acts as an oncogenic protein via activation of Sgf29 gene expression.
Sry is an important factor for sex determination and its expression in proper points and regions is strictly controlled. Except for the brain, thymus and testis, Sry expression in adult tissues is completely silenced by epigenetic regulation including DNA hypermethylation. 13 Therefore, it may be possible that deregulated expression of Sry by genetic alteration, such as gene amplification and chromosomal translocation and/or abnormal epigenetic regulation, is implicated in malignant transformation. Indeed, we found deregulated expression of Sry in two out of the four male rHCCs tested, which are also overexpressing c-Myc and Sgf29. 10 Moreover, we showed that the Sry gene, but not Sox2, was amplified in K2 cells. In addition, we previously reported that the Sry gene is located in Yp11.3, and copy number gain or amplification of this locus was observed in 11.8% (8/68) of human male HCC cases. 22 The recurrent amplification in this locus is consistent with our hypothesis that Sry could function as an oncogene in HCC. Thus, it is possible that deregulated Sry expression exhibits an oncogenic function and takes part in c-Myc-mediated male HCC development. Furthermore, high expression levels of Sry transcript in glioblastoma C6 and adrenal pheochromocytoma PC12 cells support the possibility that deregulated Sry expression is implicated in male-specific malignant conversion of various male tumors. Nonetheless, the expression level of Sry protein in C6 cells was significantly low because of vigorous degradation by the ubiquitin/proteasome system, even though the expression level of mRNA was very high. These results suggest that Sry expression is also controlled in posttranscriptional steps in a cell-specific manner.
Even though various genes are predicted as Sry target genes, only Sox9 has been shown to be a real Sry target gene. 16 Based on luciferase reporter and ChIP analyses, we demonstrated that Sgf29 is a novel Sry target gene. Sgf29, a component of the STAGA complex, binds histone H3K4me2/3 marks and gives rise to histone H3 acetylation to activate transcription. 8, 9 Among the subunits of the STAGA complex, TRRAP is essential for recruiting c-Myc to regulate transcription. 5 We observed that downregulation of Sry suppressed anchorage-independent growth, invasion and tumorigenicity of rHCC cells accompanying downregulation of LDHA and MTA1, which are involved in c-Myc-mediated malignant transformation, [23] [24] [25] [26] whereas ectopic expression of Sry exhibited the opposite effects. Furthermore, it has been reported that deregulated c-Myc expression induces dependence on AMPKrelated kinase 5/NUAK1 for maintaining metabolic homeostasis 27 and has a central role in the malignant conversion of preneoplastic liver lesions. 1 Thus, these facts strongly suggest that acquirement of deregulated Sry expression is a critical step for c-Myc target gene expressions via the STAGA complex.
c-Myc has a central role during malignant conversion of human and rodent HCCs 1,10,17,18 and requires for Sgf29-containing STAGA HAT complex to enhance c-Myc target gene expressions. 10 In this study, we identified that Sry induces Sgf29 gene expression, which is essentially needed for c-Myc-dependent gene expressions such as LDHA and MTA1 (Figure 6a) . Moreover, taking into consideration the fact that SRY gene was amplified in some hHCCs, 22 it seems that deregulation of both c-Myc and Sry expressions were functionally unified, at least in part, via elevated expression of Sgf29 in the downstream of Sry signaling. Therefore, it is highly possible that abnormal expression of Sry is specifically involved in malignant conversion of some male HCCs together with c-Myc.
Involvement of Sry in male-specific malignant conversation S Murakami et al
To date, only two factors, WT1, Wilms' tumor suppressor gene product, and Sox9, whose expressions are coupled with Sry function in sex determination, take part in malignant transformation. WT1 induces Sry expression in the embryonic stage via binding to the Sry promoter and its deregulated expression is involved in KRAS-driven oncogenesis. 28, 29 Sox9 is also required for testis formation and epithelial-mesenchymal transition in embryogenesis and chondrogenesis, and its deregulated expression is implicated in malignant transformation. 16, 29, 30 Thus, these facts partly support the possibility that Sry acts as an oncogenic protein, although we cannot completely role out the participation of WT1 and Sox9 in hepatocarcinogenesis at present. The suggestion that tumors are maintained by their own stem cells, the so-called cancer stem cells (CSCs), has had an influence on the latest cancer research. The growth of tumors is fueled by a limited number of CSCs that are capable of self-renewal, whereas most of the tumors consist of rapidly proliferating cells and postmitotic differentiated cells. 31 CSCs also participate in were cultured in the media supplemented with 5% (e) and 0.5% FBS (f ), and the cell number was counted. *Significant difference from the control (Po0.01), n ¼ 3. (g and h) Sry knockdown suppressed anchorage-independent growth. Cells (1 Â 10 3 cells per well) were cultured in soft agar containing 5% FBS. After 2 weeks, the number of colonies formed was photographed (g) and counted for colony number (h) after staining with 1-p-iodephenyl-p-nitrophenyltetrazolium chloride (INT). *Significant difference from V1 cells (Po0.01), n ¼ 3. Arrowhead presents an invasive cell. (i and j) Sry knockdown inhibits invasion. Invasion potencies of V1 and ASSry-1/2 K2 transfectants were assayed by the Matrigel-coated chamber plate (BD Biosciences). Cells (6 Â 10 4 cells) were seeded and incubated for 48 h. Invaded cells on the lower surface of the membrane were photographed (i) and the cell number was counted (j) after staining with crystal violet. *Significant difference from V1 cells (Po0.05), n ¼ 3. (k and l) Ectopic expression of antisense Sry RNA inhibits tumorigenicity. V1, ASSry-1/2 K2 transfectants were subcutaneously injected into severe-combined immunodeficiency virus mice (5 Â 10 4 cells per animal). After 6 weeks, the tumors formed were photographed (k) and tumor volumes were measured every other day (l). *Significant difference from V1 cells (Po0.05), n ¼ 5.
acquirements for drug resistance, invasiveness, metastasis and tumor redevelopment. [32] [33] [34] [35] We previously reported that, by flow cytometric analysis with rhodamine 123, side-population (SP) cells corresponding to CSCs were estimated to be 89% of the rHCC K2 cell population, in which stemness genes including sox2, nanog, klf4, bmi1 and E-ras were expressed together with c-myc. 20, 36 Therefore, it seems that Sry partly contributes to maintaining CSCs in rHCCs via activation of c-Myc function by the Sgf29/STAGA complex, suggesting that targeting Sry is a valid strategy in eliminating c-Myc-involved HCCs including CSCs, as did Sgf29. 10 
MATERIALS AND METHODS

Cell cultures and reagents
K2 cells were cultured in Dulbecco's modified Eagle's medium (NISSUI, Tokyo, Japan) containing 5% FBS as described previously. 10 rHCC cells (AH66tc, AH70tc, dRLa-74 and dRLa-84), rat glioblastoma C6, rat adrenal pheochromocytoma PC12 and rat embryonic fibroblast REF52 were obtained from the Japanese Cancer Resources Bank (Tokyo, Japan). MG132 was obtained from Sigma-Aldrich (St Louis, MO, USA).
RT-PCR
Total RNAs were prepared by the acidic guanidine thiocyanate/phenol/ chloroform method as described previously. 18 RT reactions were performed using total RNAs and Moloney murine leukemia virus reverse transcriptase, according to the manufacturer's instructions (Invitrogen, Carlsbad, CA, USA). RT reaction mixtures were subjected to PCR amplification using specific primers as follows: Sry, Western blotting Cells were lysed with sodium dodecyl sulfate sample buffer (62.5 mM TrisHCl, pH 6.8, 2% sodium dodecyl sulfate, 10% glycerol and 5% dithiothreitol). Aliquots of 10 or 30 mg of cell lysate were heated at 95 1C for 5 min and subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Proteins were transferred to a clear blot membrane (Atto Bioscience, Tokyo, Japan). Membranes were blocked in 20 mM Tris-HClbuffered saline (pH 7.4) and 0.01% Tween-20 containing 5% non-fat dry milk for 1 h at room temperature and incubated at 4 1C overnight with antiSry antibody 1:500 (Santa Cruz Biotechnology, Santa Cruz, CA, USA), antiSgf29 antibody 1:500, 10 anti-LDHA antibody 1:1000 (Santa Cruz Biotechnology), anti-MTA1 antibody 1:1000 (Santa Cruz Biotechnology), anti-ODC antibody 1:400 (Sigma-Aldrich) or anti-actin antibody 1:200 (Sigma-Aldrich). After washing three times with 20 mM Tris-HCl-buffered saline (pH 7.4) containing 0.01% Tween-20, membranes were incubated with adequate secondary antibodies. Anti-mouse immunoglobulin G conjugated with horseradish peroxidase 1:5000 (Sigma-Aldrich), antirabbit immunoglobulin G conjugated with horseradish peroxidase 1:5000 (Cell Signaling Technology, Danvers, MA, USA) or anti-goat immunoglobulin G conjugated with horseradish peroxidase 1:5000 (Santa Cruz Biotechnology) was used as a secondary antibody as indicated. Signals were visualized with the ECL system (Amersham Biosciences, Buckinghamshire, UK).
Genomic PCR
Genomic DNAs were prepared using the GeneElute Mammalian Genomic DNA Miniprep Kit (Sigma-Aldrich). PCR analysis was performed using specific primers as follows: Sry, 
Expression vector constructions and their stable transfectants
Full-length Sry cDNA was amplified using specific primers: 5 0 -TAAGGATC CATGGAGGGCCATGTC-3 0 (5 0 -primer) and 5 0 -TAACTCGAGGTGGAACTGG TGCTG-3 0 (3 0 -primer). Sense and antisense Sry expression vectors were constructed by the insertion of sense and antisense Sry cDNAs into pcDNA3-CMV (Invitrogen) and were designated as pcDNA3-Sry and pcDNA3-anti-Sry, respectively. These vectors were introduced into K2, dRLa-74 and dRLh-84 cells by Lipofectamine PLUS (Invitrogen) and cultured in the presence of 1 mg/ml G418 (Wako, Tokyo, Japan) for selection. Stable transfectants of vacant pcDNA3-CMV, pcDNA3-Sry and pcDNA3-anti-Sry were termed V1, Sry-1/2 and ASSry-1/2 as K2, dRLa-74 and dRLh-84 subcell lines, respectively.
Luciferase reporter assay
Rat Sgf29 promoter regions ( À 1232 to À 53 and À 381 to À 53) were amplified by PCR using specific primers: 5 0 -GTCTCGAGAGTC TGGGTGCTAAAATAG-3 0 (5 0 -primer), 5 0 -GGCTCGAGTTCTAAACCTAAGACT GC-3 0 (5 0 -primer) and the same5 0 -GCGATATCAAACGTAGTTCTTCGATAC-3 0 (3 0 -primer), respectively, and were inserted into the pTRE2-Luc vector (Clontech, Palo Alto, CA, USA). The respective reporter plasmids were termed Sgf29( À 1232)-Luc and Sgf29( À 381)-Luc. For the luciferase assay, COS-7 cells (1 Â 10 5 cells per 35-mm dish) were transfected with 2 mg pcDNA-Sry, 1 mg of Sgf29-Luc and 0.1 mg of the b-galactosidase expression vector pcDNA3.1/Myc-His/LacZ (Invitrogen) using Lipofectamine PLUS (Invitrogen). After 24 h, luciferase activities were determined by the Promega luciferase assay kit (Promega, Madison, WI, USA) using a Luminous CT9000D luminometer (Diaiatron, Tokyo, Japan). Reporter gene activities were normalized using b-galactosidase activity as an internal control.
ChIP assay
The ChIP assay was carried out as described previously.
18 K2 cells were crosslinked with 1% formaldehyde for 10 min The nuclear fraction was isolated and sonicated to shear genomic chromatin; clarified by centrifugation; precleared with protein A-Sepharose; and immunoprecipitated with anti-Sry antibody (Santa Cruz Biotechnology), antiacetylated histone H3 antibody (Upstate Biotechnology, Lake Placid, NY, USA), or mouse normal serum. Resulting immunoprecipitates were heated at 65 1C for 6 h and then digested with proteinase K at 45 1C for 1 h. DNA was purified by phenol/chloroform extraction. PCR was carried out on the purified DNA using specific primers for the Sgf29 proximal promoter region ( À 381 to À 53) as described above.
Colony-forming assay Suspended 1 Â 10 3 K2, 1 Â 10 4 dRLa-74 or 1 Â 10 4 dRLh-84 cells in 0.33% agar medium containing 5% FBS were layered on a 0.5% agar-containing dish. After 2 weeks, colonies were stained with 0.25% 1-p-iodophenyl-pnitrophenyl-5-phenyltetrazolium chloride (Sigma-Aldrich) and the number of colonies (4100 mm in diameter) was scored.
Matrigel invasion assay
For the invasion assay, 6 Â 10 4 cells were plated on the top chamber with a Matrigel-coated membrane (24-well insert; pore size, 8 mm) (BD Biosciences, Bedford, MA, USA) in medium without serum, and medium supplemented with 5% FBS was used as a chemoattractant in the lower chamber. After 48 h, cells on the lower surface of the membrane were stained with crystal violet and counted.
Tumorigenesis
Cells were resuspended in phosphate-buffered saline and were subcutaneously inoculated (5 Â 10 4 cells per 200 ml phosphate-buffered saline per flank) into 5-week-old severe-combined immunodeficiency virus mice (C.B17/Icr-scid/scid Jcl) (Clea Japan, Tokyo, Japan). Tumor volumes were calculated according to the formula V ¼ a Â b 2 Â 0.5, where a is the largest diameter and b the smallest diameter of the tumor. 17 Mouse care and handling conformed to the National Institutes of Health guidelines for animal research. The experimental protocols were approved by the Institutional Animal Care and Use Committee.
Statistical analysis
All data were expressed as mean ± s.e. of the indicated number of experiments. Comparisons of data were carried out by the Student's t-test. Differences were considered significant at Po0.05. The software package KaleidaRraph 3.6 (Synergy Software, Reading, PA, USA) was used for statistical analysis.
